Orphazyme A/S
ORPH
ORPH was delisted on the 30th of March, 2022.
4 hedge funds and large institutions have $8K invested in Orphazyme A/S in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 16 closing their positions.
0% more call options, than puts
Call options by funds: $4K | Put options by funds: $4K
80% less funds holding
Funds holding: 20 → 4 (-16)
100% less capital invested
Capital invested by funds: $3.31M → $8K (-$3.31M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 16
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$656K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$426K |
| 3 |
Two Sigma Investments
New York
|
-$340K |
| 4 |
PA
Profund Advisors
Bethesda,
Maryland
|
-$307K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$276K |
ORPH Hedge Fund Activity: Q1 2022 in Review
4 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Orphazyme A/S (ORPH) for Q1 2022, worth a combined $8K — down 100% from $3.31M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ORPH and 0 opened new positions — a net loss of 16 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $656K sold.
- 4 institutional investors held Orphazyme A/S (ORPH) as of Q1 2022, down from 20 in Q4 2021.
- Funds reported $8K of Orphazyme A/S stock for Q1 2022, down 100% quarter-over-quarter.
- 0 funds opened new Orphazyme A/S positions in Q1 2022 and 16 closed out, a net change of -16 holders.
- The largest Orphazyme A/S seller in Q1 2022 was Renaissance Technologies, an estimated $656K sold.
Based on aggregated 13F filings for Q1 2022.